Insider Selling: Protagonist Therapeutics Inc (PTGX) Insider Sells 875 Shares of Stock
Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $20.00, for a total transaction of $17,500.00. Following the transaction, the insider now directly owns 4,697 shares in the company, valued at $93,940. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
David Y. Liu also recently made the following trade(s):
- On Monday, November 13th, David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $118,790.00.
Protagonist Therapeutics Inc (PTGX) traded up $0.08 during mid-day trading on Thursday, hitting $19.46. 140,700 shares of the stock traded hands, compared to its average volume of 101,773. Protagonist Therapeutics Inc has a one year low of $8.00 and a one year high of $21.68. The firm has a market cap of $397.55 and a PE ratio of -7.00.
Hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter worth $114,000. Bank of Montreal Can lifted its stake in shares of Protagonist Therapeutics by 1,086.0% in the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock worth $123,000 after acquiring an additional 5,430 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Protagonist Therapeutics by 60.8% in the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after acquiring an additional 3,617 shares during the period. Teachers Advisors LLC lifted its stake in shares of Protagonist Therapeutics by 71.4% in the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock worth $183,000 after acquiring an additional 6,757 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Protagonist Therapeutics by 8.5% in the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock worth $188,000 after acquiring an additional 1,300 shares during the period. Institutional investors own 39.68% of the company’s stock.
Several research analysts have issued reports on PTGX shares. Zacks Investment Research downgraded shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 18th. BMO Capital Markets reduced their target price on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, October 19th. Finally, BidaskClub cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Protagonist Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $32.67.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Protagonist Therapeutics Inc (PTGX) Insider Sells 875 Shares of Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/01/18/insider-selling-protagonist-therapeutics-inc-ptgx-insider-sells-875-shares-of-stock.html.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.